Glutathione Precursors for Mild Cognitive Impairment
Trial Summary
What is the purpose of this trial?
Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanisms linked to GSH for cognitive impairment (and improvement) by studying humans with mild cognitive impairment who will be evaluated 12-weeks after receiving either N-acetylcysteine and glycine (GSH precursors), or receiving alanine, and a further 12-weeks after stopping these supplements.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment N-acetylcysteine plus Glycine for mild cognitive impairment?
Research suggests that N-acetylcysteine, a component of the treatment, may help increase levels of glutathione, an important antioxidant that declines in Alzheimer's disease and mild cognitive impairment. This could potentially reduce oxidative stress and improve cognitive function, although more direct evidence is needed.12345
Is N-acetylcysteine safe for humans?
How is the drug N-acetylcysteine plus Glycine unique for treating mild cognitive impairment?
Eligibility Criteria
This trial is for older adults with mild cognitive impairment, which is an early stage of memory loss. Participants should not have been hospitalized recently, have diabetes, severe kidney or liver disease, a history of stroke or heart issues, or untreated depression.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either N-acetylcysteine and glycine or alanine for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Alanine
- Glycine
- N-acetylcysteine
- N-acetylcysteine plus Glycine
N-acetylcysteine is already approved in United States, European Union for the following indications:
- Acetaminophen overdose
- Chronic bronchitis
- Cystic fibrosis
- Mucolytic agent
- Paracetamol overdose
- Chronic bronchitis
- Cystic fibrosis
- Mucolytic agent
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baylor College of Medicine
Lead Sponsor
The Methodist Hospital Research Institute
Collaborator